Pfizer Inc
Close on Oct 30, 2026Market cap $173.95BP/E 40.2Yield 5.64%
Pfizer Abrysvo (bivalent RSV vaccine by Year
Abrysvo (bivalent RSV vaccine — maternal & older adults) — International revenues ($M) ($M)
Pfizer Abrysvo (bivalent RSV vaccine: $491M in FY2025, up 206.9% from a year earlier.
Where the FY2025 figure comes from
“|| Abrysvo | 1,033 | 755 | 37% | 36% | 542 | 594 | (9%) | 491 | 160 | * | *”
Source: Form 8-K (Earnings / Guidance Release) (pfe-12312025xex99.htm, filed 2026-02-03) ↗
Reported in Form 8-K Revenue Tables & Form 10-Q / 10-K Segment Footnotes.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Abrysvo (bivalent RSV vaccine — maternal & older adults) — International revenues ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 491 | +206.9% | Form 8-K (Earnings / Guidance Release) (pfe-12312025xex99.htm, filed 2026-02-03) ↗ |
| FY2024 | Dec 31, 2024 | 160 | +7,900.0% | Form 8-K (Earnings / Guidance Release) (pfe-12312025xex99.htm, filed 2026-02-03) ↗ |
| FY2023 | Dec 31, 2023 | 2 | – | Form 8-K (Earnings / Guidance Release) (pfe-12312024xex99.htm, filed 2025-02-04) ↗ |
Cite this data
StockData. (2026). Pfizer Abrysvo (bivalent RSV vaccine ($M), annual FY2023–FY2025 [Data set]. Compiled from Pfizer SEC filings and investor materials. https://stockdatahq.com/stocks/pfe/kpis/abrysvo-intl
See every metric in the Pfizer KPI table. Data updated Nov 2, 2026.